An orally available SF3b inhibitor, H3B-8800, preferentially inhibited tumor growth in spliceosome-mutant cancer cells, such as SF3B1 K700E, in vitro and in vivo by predominantly binding with short GC-rich regions (160). This evidence concerns the gene SF3B1 and cancer.